Silo Pharma Inc.'S (SILO) Ketamine Study Produces Positive E...| MENAFN.COM

Wednesday, 10 August 2022 06:01 GMT

Silo Pharma Inc.'S (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain


(MENAFN- Investor Brand Network)

  • Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system
  • Results of study demonstrated Silo's topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point
  • Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses

Silo Pharma (OTCQB: SILO) , a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics ( ).

Results of the small animal study produced positive endpoint results, demonstrating that Silo's topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company's newsroom at 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime . As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text“Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit 

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: 

BioMedWire (BMW)
San Francisco, California

415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork .

MENAFN03082022000224011066ID1104642236


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.